John Holte Od Medicare Supplier Location: 6487 Cedar Hills Dr, Cannon Falls, Minnesota 55009 Phone: (507) 263-3949 |
News Archive
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The U.S. Department of Veterans Affairs (VA) has awarded QuadraMed® Corporation, a leading provider of healthcare technologies and services, a five-year, $211 million contract to implement its Quantim® Coding, Compliance and Abstracting solution. The comprehensive, integrated solution will improve the VA healthcare system's coding productivity and accuracy through real-time compliance monitoring and customizable billing processes.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
Patients with recurrent glioblastoma multiforme treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.
› Verified 2 days ago